| 28 |
“Even Big Pharma Has Pulled Out of Antibiotic Development”… LyseNTech Selected for Deep Tech TIPS |
LyseNTech |
2026-08-10 |
41 |
| 27 |
LyseNTech Selected as a Final Awardee for a Ministry of Health and Welfare R&D Project… “Leading the Fight Against Antimicrobial Resistance” |
LyseNTech |
2026-07-20 |
92 |
| 26 |
LyseNTech’s Preclinical Study of Endolysin-Based Antibiotic Published in International Journal |
LyseNTech |
2026-07-20 |
74 |
| 25 |
Agreement for joint research between LyseNTech and Zoonotic Infectious Disease Research Institute of Chonbuk National University |
LyseNTech |
2024-05-27 |
2444 |
| 24 |
Approval of IND for phase I clinical trial for Endolysin LNT103 |
LyseNTech |
2024-04-03 |
2528 |
| 23 |
LyseNTech selected for the GloPID-R project |
LyseNTech |
2024-04-03 |
2521 |
| 22 |
LyseNTech filed IND for phase 1 clinical trial of its endolysin |
LyseNTech |
2023-11-23 |
2600 |
| 21 |
LyseNTech acquired US patent for endolysin LNT103 |
LyseNTech |
2023-11-22 |
2501 |
| 20 |
LyseNTech won the grand prize at the 2023 Gyeonggi Startup Investment Conference & Global Day |
LyseNTech |
2023-11-03 |
2502 |
| 19 |
Heejoon Myung, CEO of LyseNTech, presented at the 2023 Korean Society of Infectious Diseases |
LyseNTech |
2023-11-03 |
2518 |
